Secondary Logo

Journal Logo

Correspondence

Men and mortality: sex inequality in health outcomes

Cornell, Morna; Myer, Landon

Author Information
doi: 10.1097/QAD.0b013e32835e399b
  • Free

We read with interest the recent systematic review and meta-analysis which summarized the published evidence that, in many settings of sub-Saharan Africa, men receiving antiretroviral therapy (ART) appear to experience greater mortality on treatment compared with women [1].

We concur with the authors that their finding conflicts with current views on sex inequality in Africa. For the most part, funding agencies, governments, researchers and the general public have struggled to acknowledge that, contrary to the general discourse on sex inequality in the HIV epidemic, in fact men appear to be widely disadvantaged in their access to and outcomes on ART [2]. However, we are concerned that some of the remarks of Druyts et al.[1] seem to propagate the dominant messages of women's disempowerment. Despite reporting overwhelming evidence for male sex inequity in ART programme outcomes, the authors conclude that their findings ‘should not be used to argue strongly in favour of men's rights, but rather to promote equal access to treatment and care, regardless of sex’. We question the implicit assumption that advocating for men's rights in a situation of sex inequity automatically undermines the rights of women.

In recent years, there has been a plethora of studies reporting elevated risk for men compared with women in ART programmes [3–7]. Many such studies have concluded that this may be due to individual level risk factors related to men's poorer ‘health-seeking behaviour’. Researchers have suggested, for example, that men are less likely to seek care for HIV [8]; that when they seek care they do so at a later stage than women [9]; that they may be less likely to adhere to treatment [10]; and that they are more likely lost to follow-up [11] and consequently to die.

We recently explored these explanations in a study on sex and survival on ART among 46 201 adults in a large multicentre analysis of South African adult ART programmes [12]. We found that none of the mechanisms fully explained men's elevated risk of mortality on ART. Indeed, it appeared that the reasons may be unrelated to ART and even to HIV: whereas men in these programmes had a 31% higher risk of death than women, in an age-standardized hypothetical cohort of HIV-negative individuals, men had twice the risk of death compared with women. Although these findings are intriguing, our study was not designed to explore non-HIV mortality and we would welcome research that sheds light on the mechanisms which increase men's general risk of mortality compared with women.

So men are indeed more likely than women to die on ART but this sex difference may be even greater outside ART programmes than within. Surely we should be trying to understand the factors that increase men's mortality risk rather than pitting the interests of men and women against each other?

Acknowledgements

Conflicts of interest

There are no conflicts of interest.

References

1. Druyts E, Dybul M, Kanters S, Nachega J, Birungi J, Ford N, et al. Male gender and the risk of mortality among individuals enrolled in antiretroviral treatment programs in Africa: A systematic review and meta-analysis.AIDS; 27:417–425. 10.1097/QAD.1090b1013e328359b328389b.
2. Cornell M, McIntyre J, Myer L. Men and antiretroviral therapy in Africa: our blind spot. Tropical Medicine & International Health 2011; 16:828–829.
3. Stringer JSA, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia.JAMA J Am Med Assoc 2006; 296:782–793.
4. DeSilva M, Merry S, Fischer P, Rohrer J, Isichei C, Cha S. Youth, unemployment and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care 2009; 21:70–77.
5. Taylor-Smith K, Tweya H, Harries A, Schoutene E, Jahn A. Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Med J 2010; 22:49–56.
6. Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, Aris E, et al. Gender differences in antiretroviral treatment outcomes among HIV-infected adults in Dar es Salaam Tanzania. AIDS 2011; 201125:1189–1197.
7. Mills E, Bakanda C, Birungi J, Chan K, Hogg R, Ford N, et al. Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc 2011; 14:52.
8. Nattrass N. Gender and access to antiretroviral treatment in South Africa. Feminist Economics 2008; 14:19–36.
9. Braitstein P, Boulle A, Nash D, Brinkhof M, Dabis F, Laurent C, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 2008; 17:47–55.
10. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, et al. Adherence to Highly Active Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African Adults. JAIDS J Acquir Immune Defic Syndr 2006; 43:78–84.10.1097/1001.qai.0000225015.0000243266.0000225046..
11. Ochieng-Ooko V, Ochieng D, Sidle J, Holdsworth M, Wools-Kaloustian K, Siika A, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ 2010; 88:681–688.
12. Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, et al. Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. PLoS Med 2012; 9:e1001304.
© 2013 Lippincott Williams & Wilkins, Inc.